Clearside Biomedical may be sliding down financialy. It has an above-average probability of going through some form of financial hardship next quarter. At present, Clearside Biomedical's Property Plant And Equipment Net is projected to increase significantly based on the last few years of reporting. The current year's Net Debt is expected to grow to about 13.3 M, whereas Other Current Liabilities is forecasted to decline to about 2.7 M. Key indicators impacting Clearside Biomedical's financial strength include:
Investors should never underestimate Clearside Biomedical's ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Clearside Biomedical's cash flow, debt, and profitability to make informed and accurate decisions about investing in Clearside Biomedical.
Net Income
(30.7 Million)
Clearside
Select Account or Indicator
Market Cap
Enterprise Value
Price To Sales Ratio
Ptb Ratio
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Stock Based Compensation To Revenue
Capex To Depreciation
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Net Income Per Share
Payables Turnover
Sales General And Administrative To Revenue
Research And Ddevelopement To Revenue
Capex To Revenue
Cash Per Share
Pocfratio
Interest Coverage
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Revenue Per Share
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Long Term Debt To Capitalization
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Cash Ratio
Cash Conversion Cycle
Operating Cash Flow Sales Ratio
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Gross Profit Margin
Price Fair Value
Return On Equity
Sale Purchase Of Stock
Change In Cash
Stock Based Compensation
Free Cash Flow
Begin Period Cash Flow
Other Cashflows From Financing Activities
Depreciation
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Change In Working Capital
Investments
Net Borrowings
Total Cashflows From Investing Activities
Change To Operating Activities
Other Cashflows From Investing Activities
Change To Netincome
Change To Liabilities
Change To Inventory
Cash And Cash Equivalents Changes
Cash Flows Other Operating
Change To Account Receivables
Issuance Of Capital Stock
Total Assets
Short Long Term Debt Total
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Property Plant And Equipment Net
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Non Currrent Assets Other
Cash And Short Term Investments
Common Stock Total Equity
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Non Current Liabilities Total
Other Current Assets
Other Stockholder Equity
Total Liab
Property Plant And Equipment Gross
Total Current Assets
Accumulated Other Comprehensive Income
Common Stock
Other Liab
Net Tangible Assets
Other Assets
Long Term Debt
Deferred Long Term Liab
Short Long Term Debt
Short Term Debt
Property Plant Equipment
Long Term Debt Total
Capital Surpluse
Current Deferred Revenue
Retained Earnings Total Equity
Inventory
Net Invested Capital
Net Working Capital
Capital Stock
Capital Lease Obligations
Non Current Liabilities Other
Net Receivables
Depreciation And Amortization
Interest Expense
Other Operating Expenses
Operating Income
Ebit
Research Development
Ebitda
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Income Tax Expense
Selling General Administrative
Total Revenue
Gross Profit
Net Income From Continuing Ops
Cost Of Revenue
Net Income Applicable To Common Shares
Non Operating Income Net Other
Reconciled Depreciation
Net Interest Income
Probability Of Bankruptcy
Understanding current and past Clearside Biomedical Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Clearside Biomedical's financial statements are interrelated, with each one affecting the others. For example, an increase in Clearside Biomedical's assets may result in an increase in income on the income statement.
Please note, the presentation of Clearside Biomedical's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Clearside Biomedical's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Clearside Biomedical's management manipulating its earnings.
Clearside Biomedical Stock Summary
Clearside Biomedical competes with Oric Pharmaceuticals, Lyra Therapeutics, Inhibrx, ESSA Pharma, and Sensei Biotherapeutics. Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia. Clearside Biomedi operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 34 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Comparative valuation techniques use various fundamental indicators to help in determining Clearside Biomedical's current stock value. Our valuation model uses many indicators to compare Clearside Biomedical value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Clearside Biomedical competition to find correlations between indicators driving Clearside Biomedical's intrinsic value. More Info.
Clearside Biomedical is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At present, Clearside Biomedical's Return On Equity is projected to increase based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Clearside Biomedical by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Clearside Biomedical Systematic Risk
Clearside Biomedical's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Clearside Biomedical volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty-four with a total number of output elements of thirty-seven. The Beta measures systematic risk based on how returns on Clearside Biomedical correlated with the market. If Beta is less than 0 Clearside Biomedical generally moves in the opposite direction as compared to the market. If Clearside Biomedical Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Clearside Biomedical is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Clearside Biomedical is generally in the same direction as the market. If Beta > 1 Clearside Biomedical moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Clearside Biomedical Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Clearside Biomedical's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Clearside Biomedical growth as a starting point in their analysis.
Price Earnings To Growth Ratio
0.38
At present, Clearside Biomedical's Price Earnings To Growth Ratio is projected to slightly decrease based on the last few years of reporting.
Clearside Biomedical March 23, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Clearside Biomedical help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Clearside Biomedical. We use our internally-developed statistical techniques to arrive at the intrinsic value of Clearside Biomedical based on widely used predictive technical indicators. In general, we focus on analyzing Clearside Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Clearside Biomedical's daily price indicators and compare them against related drivers.
When running Clearside Biomedical's price analysis, check to measure Clearside Biomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Clearside Biomedical is operating at the current time. Most of Clearside Biomedical's value examination focuses on studying past and present price action to predict the probability of Clearside Biomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Clearside Biomedical's price. Additionally, you may evaluate how the addition of Clearside Biomedical to your portfolios can decrease your overall portfolio volatility.